<?xml version="1.0"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><atom:link href="http://www.cnbc.com/id/10000108/device/rss/rss.html" rel="self" type="application/rss+xml" /><title>Health Care</title><description><![CDATA[Healthcare]]></description><link>http://www.cnbc.com/id/10000108</link><pubDate>Wed, 13 Feb 2013 17:22 GMT</pubDate><lastBuildDate>Wed, 13 Feb 2013 17:22 GMT</lastBuildDate><language>en-us</language><ttl>60</ttl><item><title>Biogen submits new MS drug for FDA approval</title><description><![CDATA[WESTON, Mass.-- Specialty drugmaker Biogen Idec said Tuesday it submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval. The company also plans to submit the drug to the European Medicines Agency in coming weeks. Shares of Biogen Idec Inc. rose $6.15, or 2.7 percent, to close Tuesday at $231.33.]]></description><link>http://www.cnbc.com/id/100755477</link><pubDate>Tue, 21 May 2013 19:13 GMT</pubDate><guid isPermaLink="false">guid_100755477</guid> </item>  <item><title>Small suburban Oklahoma City hospital damaged</title><description><![CDATA[MOORE, Okla.-- Officials say a tornado hit a small hospital in suburban Oklahoma City, but all the 30 patients inside survived. Moore Medical Center spokeswoman Kelly Wells says the hospital was &quot;pretty much destroyed&quot; after Monday&#039;s tornado.]]></description><link>http://www.cnbc.com/id/100754249</link><pubDate>Tue, 21 May 2013 13:33 GMT</pubDate><guid isPermaLink="false">guid_100754249</guid> </item>  <item><title>Ahead of the Bell: Analyst upgrades Cubist Pharma</title><description><![CDATA[The revenue hit faced by Cubist Pharmaceuticals from generic competition may not be as dramatic as it has been for other drugs, Cantor Fitzgerald said Tuesday, as it raised its rating on the drugmaker.]]></description><link>http://www.cnbc.com/id/100754147</link><pubDate>Tue, 21 May 2013 13:11 GMT</pubDate><guid isPermaLink="false">guid_100754147</guid> </item>  <item><title>Pfizer halts study of non-Hodgkin's lymphoma drug</title><description><![CDATA[Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin&#039;s lymphoma, because an interim analysis showed the drug wasn&#039;t helping patients live longer.]]></description><link>http://www.cnbc.com/id/100752343</link><pubDate>Mon, 20 May 2013 22:39 GMT</pubDate><guid isPermaLink="false">guid_100752343</guid> </item>  <item><title>Cramer’s Watch List Ahead of Big Cancer Conference</title><description><![CDATA[The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts.]]></description><link>http://www.cnbc.com/id/100752180</link><pubDate>Mon, 20 May 2013 22:26 GMT</pubDate><guid isPermaLink="false">guid_100752180</guid> </item>  <item><title>UPDATE 1-FDA staff says Merck's sleep drug effective, questions dosage</title><description><![CDATA[May 20- Merck&amp; Co&#039;s experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food and Drug Administration, but they questioned the company&#039;s proposed dosing levels.]]></description><link>http://www.cnbc.com/id/100750485</link><pubDate>Mon, 20 May 2013 12:59 GMT</pubDate><guid isPermaLink="false">guid_100750485</guid> </item>  <item><title>What's Leading Markets to New Heights?</title><description><![CDATA[Thomas Lee, Chief U.S. Equity Strategist at JPMorgan, discusses whether the markets have room to run, and explains why he believes the tech, health care and financials sectors are cheap now.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000168210</link><pubDate>Mon, 20 May 2013 12:30 GMT</pubDate><guid isPermaLink="false">guid_100750345</guid> </item>  <item><title>Actavis to Buy Warner Chilcott for $8.5 Billion</title><description><![CDATA[Generic drugmaker Actavis will buy Warner Chilcott in a stock deal valued at about $8.5 billion.]]></description><link>http://www.cnbc.com/id/100750001</link><pubDate>Mon, 20 May 2013 12:11 GMT</pubDate><guid isPermaLink="false">guid_100750001</guid> </item>  <item><title>XenoPort: Horizant likely available in early June</title><description><![CDATA[SANTA CLARA, Calif.-- Drug developer XenoPort said Friday that its treatment for restless leg syndrome, Horizant, will likely be available to U.S. patients in early June. Last month XenoPort Inc. said that there was a shortage of Horizant, with patients telling them that they were unable to fill prescriptions.]]></description><link>http://www.cnbc.com/id/100746448</link><pubDate>Fri, 17 May 2013 14:52 GMT</pubDate><guid isPermaLink="false">guid_100746448</guid> </item>  <item><title>Oncothyreon slumps on new cancer drug data</title><description><![CDATA[NEW YORK-- Shares of Oncothyreon Inc. fell Thursday after the drug developer announced new clinical trial data about an experimental lung cancer treatment that failed to improve overall survival rate. THE SPARK: Oncothyreon said that it identified some patients who appeared to live longer after treatment with Stimuvax.]]></description><link>http://www.cnbc.com/id/100743597</link><pubDate>Thu, 16 May 2013 15:54 GMT</pubDate><guid isPermaLink="false">guid_100743597</guid> </item>  <item><title>More Than a Fat Paycheck: Jobs With Obese Workers </title><description><![CDATA[Does this job make me look fat? A Gallup-Healthways survey takes a look at which jobs have high rates of obesity.]]></description><link>http://www.cnbc.com/id/100743271</link><pubDate>Thu, 16 May 2013 14:52 GMT</pubDate><guid isPermaLink="false">guid_100743271</guid> </item>  <item><title>Health Care Industry Game Changers</title><description><![CDATA[CNBC&#039;s Julia Boorstin reports on companies that are looking to increase efficiency and implement simplicity in medical care. And, Grant Verstandig,  Audax Health founder and CEO, discusses how his digital health care startup encourages consumers to make healthier lifestyle choices.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000168697</link><pubDate>Thu, 16 May 2013 12:14 GMT</pubDate><guid isPermaLink="false">guid_100742779</guid> </item>  <item><title>FDA approves Roche diagnostic for gene mutation in lung cancer</title><description><![CDATA[This marks the first companion diagnostic that detects epidermal growth factor receptor gene mutations to be approved by the U.S. Food and Drug Administration, the agency said.]]></description><link>http://www.cnbc.com/id/100736984</link><pubDate>Tue, 14 May 2013 20:53 GMT</pubDate><guid isPermaLink="false">guid_100736984</guid> </item>  <item><title>More Women Choosing Preventive Mastectomies</title><description><![CDATA[The number of women having preventive mastectomies has risen in recent years, but doctors say they have other options.]]></description><link>http://www.cnbc.com/id/100736370</link><pubDate>Tue, 14 May 2013 19:34 GMT</pubDate><guid isPermaLink="false">guid_100736370</guid> </item>  <item><title>Hospira's former chief scientific officer returns</title><description><![CDATA[LAKE FOREST, Ill.-- Drug and medical device maker Hospira Inc. said Tuesday that Dr.]]></description><link>http://www.cnbc.com/id/100736207</link><pubDate>Tue, 14 May 2013 17:16 GMT</pubDate><guid isPermaLink="false">guid_100736207</guid> </item>  <item><title>FDA approves labels with lower doses for zolpidem sleep drugs</title><description><![CDATA[The FDA in January asked zolpidem manufacturers, including NovaDel Pharma Inc and Swedish drugmaker Meda, to reduce recommended dosages on the drugs&#039; labels. The FDA recommended doses of 5 mg for women and either 5 mg or 10 mg for men for immediate-release zolpidem products such as Sanofi&#039;s Ambien.]]></description><link>http://www.cnbc.com/id/100735911</link><pubDate>Tue, 14 May 2013 15:54 GMT</pubDate><guid isPermaLink="false">guid_100735911</guid> </item>  <item><title>FDA accepts Seattle Genetics Adcetris application</title><description><![CDATA[BOTHELL, Wash.-- Drug developer Seattle Genetics Inc. said Tuesday the Food and Drug Administration has accepted its application to market the lymphatic cancer treatment Adcetris for some additional uses. Seattle Genetics expects the FDA to make a decision by Sept. 14.]]></description><link>http://www.cnbc.com/id/100735552</link><pubDate>Tue, 14 May 2013 14:29 GMT</pubDate><guid isPermaLink="false">guid_100735552</guid> </item>  <item><title>Hospitals could lose $500M in federal funds</title><description><![CDATA[MIAMI-- Hospitals nationwide could lose half a billion dollars in federal funding for uninsured patients next year under the national health overhaul _ a loss that will hit especially hard in states that decided against expanding Medicaid coverage.]]></description><link>http://www.cnbc.com/id/100735150</link><pubDate>Tue, 14 May 2013 13:04 GMT</pubDate><guid isPermaLink="false">guid_100735150</guid> </item>  <item><title>PDI moves to 1Q profit, revenue up 36 percent</title><description><![CDATA[NEW YORK-- PDI Inc., which provides sales and marketing services to the biopharmaceutical industry, said Monday that it turned a profit in the first quarter. Net income was $2.1 million, or 14 cents per share. The company had a loss of $272,000, or 2 cents per share, a year ago.]]></description><link>http://www.cnbc.com/id/100733075</link><pubDate>Mon, 13 May 2013 21:08 GMT</pubDate><guid isPermaLink="false">guid_100733075</guid> </item>  <item><title>UPDATE 2-Ranbaxy pleads guilty, to pay $500 mln in US settlement</title><description><![CDATA[*Ranbaxy says money set aside sufficient to cover costs. May 13- Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.]]></description><link>http://www.cnbc.com/id/100732543</link><pubDate>Mon, 13 May 2013 18:06 GMT</pubDate><guid isPermaLink="false">guid_100732543</guid> </item>  <item><title>Drugs Costs Face Vast Disparity Under Obamacare</title><description><![CDATA[Where you live could make a huge difference in what you&#039;ll pay for medications under Obamacare.]]></description><link>http://www.cnbc.com/id/100731024</link><pubDate>Mon, 13 May 2013 12:23 GMT</pubDate><guid isPermaLink="false">guid_100731024</guid> </item>  <item><title>UPDATE 3-Elan's $1 bln drug royalty deal aids bid defence</title><description><![CDATA[DUBLIN, May 13- Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.]]></description><link>http://www.cnbc.com/id/100731231</link><pubDate>Mon, 13 May 2013 12:15 GMT</pubDate><guid isPermaLink="false">guid_100731231</guid> </item>  <item><title>UPDATE 1-U.S. FDA approves Glaxo/Theravance drug for COPD lung disease</title><description><![CDATA[May 10- The U.S. Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both. The drug, Breo, is an inhaled treatment made by British drugmaker GlaxoSmithKline Plc and Theravance Inc of the United States.]]></description><link>http://www.cnbc.com/id/100727563</link><pubDate>Fri, 10 May 2013 15:35 GMT</pubDate><guid isPermaLink="false">guid_100727563</guid> </item>  <item><title>NYC wins $70M from 44 pharmaceutical companies</title><description><![CDATA[NEW YORK-- New York City has won nearly $70 million from 44 pharmaceutical companies in a Medicaid fraud lawsuit over the pricing of prescription drugs. The New York City Law Department said Thursday that the city has already been paid about $60 million with the last settlements being processed.]]></description><link>http://www.cnbc.com/id/100727443</link><pubDate>Fri, 10 May 2013 14:57 GMT</pubDate><guid isPermaLink="false">guid_100727443</guid> </item>  <item><title>Intuitive Surgical Issues Urgent Notification</title><description><![CDATA[The maker of the da Vinci surgical robot has flagged a potential issue, reports CNBC&#039;s Herb Greenberg.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000167613</link><pubDate>Fri, 10 May 2013 14:25 GMT</pubDate><guid isPermaLink="false">guid_100727430</guid> </item>  <item><title>Execs' Cushy Health Insurance May Trigger Fines</title><description><![CDATA[Employers offering plusher health benefits to higher-ups may be fined $100 a day for each worker who doesn&#039;t get the perk.]]></description><link>http://www.cnbc.com/id/100723962</link><pubDate>Thu, 09 May 2013 15:37 GMT</pubDate><guid isPermaLink="false">guid_100723962</guid> </item>  <item><title>Break Out the Bandages, Santelli's Tackling ObamaCare</title><description><![CDATA[CNBC&#039;s Rick Santelli maps out the problems he sees with the Patient Protection and Affordable Care Act.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000167303</link><pubDate>Thu, 09 May 2013 14:52 GMT</pubDate><guid isPermaLink="false">guid_100724131</guid> </item>  <item><title>Drug Spending Drops for the First Time in 55 Years</title><description><![CDATA[Drug patent expirations resulted in less spending on medicines in the U.S. for the first time in at least 55 years.]]></description><link>http://www.cnbc.com/id/100723330</link><pubDate>Thu, 09 May 2013 12:31 GMT</pubDate><guid isPermaLink="false">guid_100723330</guid> </item>  <item><title>U.S. lawmakers advance bill on prescription drug tracking</title><description><![CDATA[WASHINGTON, May 8- A U.S. House of Representatives panel advanced a bill on Wednesday on how the federal government should track prescription drugs as they move through the distribution chain, over the objections of some Democrats who said the proposal did not go far enough to ensure safety.]]></description><link>http://www.cnbc.com/id/100721464</link><pubDate>Wed, 08 May 2013 20:40 GMT</pubDate><guid isPermaLink="false">guid_100721464</guid> </item>  <item><title>REUTERS SUMMIT-Faster drug approvals a tonic for pharma industry</title><description><![CDATA[After approvals last year from the FDA for 39 novel medicines- a record only beaten in 1996- the healthy pace has continued into 2013.. And drugmakers are getting further help from a new FDA program to accelerate life-saving therapies designated as a &quot;breakthrough,&quot; opening to door to earlier approval based on quicker studies, where clinical data is compelling.]]></description><link>http://www.cnbc.com/id/100721007</link><pubDate>Wed, 08 May 2013 18:49 GMT</pubDate><guid isPermaLink="false">guid_100721007</guid> </item> </channel>   </rss>